A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
Clinical trial NCT05227703 · COMPLETED
Trial details
- NCT number
- NCT05227703
- Sponsor
- AbbVie
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-05
- Primary completion
- 2024-08-15
- Enrollment
- 391
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.